Prelude Capital Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Prelude Capital Management’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-200	Closed	-$21K	–	2293
2015 Q1	$21K	Buy	+200	New	+$19.1K	﹤0.01%	1738
2014 Q3	–	Sell	-520	Closed	-$47K	–	2325
2014 Q2	$47K	Buy	520 +180	+53%	+$11K	0.01%	1383
2014 Q1	$18K	Buy	+340	New	+$11.2K	﹤0.01%	1713

Other funds holding PTX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Prelude Capital Management's PTX Position: Q4 2015 in Review

Prelude Capital Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2015, closing a stake of 1,600 shares — an estimated $51K sold.

Prelude Capital Management first reported a position in PTX in Q1 2014 and held it in 7 quarters. The position peaked at $320K in Q4 2014. 101 funds tracked by Wall St. Rank hold PTX as of Q4 2015.

Prelude Capital Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2015 after selling out during the quarter.
Prelude Capital Management sold 1,600 Pernix Therapeutics Holdings, Inc. shares in Q4 2015, an estimated $51K.
Prelude Capital Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2014 and held it in 7 quarters.
Prelude Capital Management's Pernix Therapeutics Holdings, Inc. position peaked at $320K in Q4 2014.
101 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2015.

Based on Prelude Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.